c-Met is a proto-oncogene responsible for encoding the high-affinity receptor for hepatocyte growth factor (HGF). Hepatocyte growth factor is also known as scatter factor which participates in HGF/c-MET signaling pathway. This pathway plays vital role in mitogenesis and morphogenesis during embryonic development and wound healing. The controlled natural activity of c-Met and HGF is important in mammalian development, tissue maintenance, and repair. Binding of HGF to c-MET receptor induces several biological responses collectively known as invasive growth program. These responses are elicited due to activation of several pathways such as RAS pathway, PI3K pathway, STAT pathway, beta-catenin pathway and Notch pathway. However, dysregulation of the HGF/c-MET signaling pathway has been associated with the progression of cancers through activation of oncogenic pathways, angiogenesis and metastasis.
The major cancers such as breast, colon and non-small-cell lung carcinoma (NSCLC) are being examined for efficacy with c-MET / HGF inhibitors. Several small molecule c-Met kinase inhibitors have demonstrated clinical efficacy in cancer treatment and many clinical trials are underway. However, as the small molecule inhibitors lack specificity or selectivity they can cause toxicity. Therefore, researchers are increasing focus to develop antibody therapeutics against c-Met or HGF.
Market Analysis and Insights: Global C-MET / HGF Inhibitors Market
The global C-MET / HGF Inhibitors market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
Global C-MET / HGF Inhibitors Scope and Segment
The global C-MET / HGF Inhibitors market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global C-MET / HGF Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
The major regions covered in the report are North America, Europe, Asia-Pacific, South America, Middle East & Africa, etc. The report has specifically covered major countries including U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc. It includes revenue and volume analysis of each region and their respective countries for the forecast years. It also contains country-wise volume and revenue from the year 2016 to 2021. Additionally, it provides the reader with accurate data on volume sales according to the consumption for the same years.
By the product type, the market is primarily split into
C-Met Biologic Inhibitors
Small Molecule C-Met Inhibitors
HGF Antagonist Antibodies
C-Met Antagonist Antibodies(MetMAb)
HGF Kringle Variant Antagonists
By the end users/application, this report covers the following segments
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Sales
Competitive Landscape:
The report provides a list of all the key players in the C-MET / HGF Inhibitors market along with a detailed analysis of the strategies, which the companies are adopting. The strategies mainly include new product Developments, research, and Developments, and also provides revenue shares, company overview, and recent company Developments to remain competitive in the market.
The C-MET / HGF Inhibitors key manufacturers in this market include:
Abxign
Abbott Laboratories
Amgen
ArQule
Astex Therapeutics
AVEO Pharmaceuticals
Bristol-Myers Squibb(BMS)
Chroma Therapeutics
Daiichi Sankyo
Deciphera Pharmaceuticals
Eisai
Eli Lilly
Exelixis
Genmab
Galaxy Biotech
GlaxoSmithKline(GSK)
Hutchison MediPharma
Johnson & Johnson
Kringle Pharmaceuticals
Merck
Methylgene
Novartis
Pfizer
ProMetic BioTherapeutics
Takeda Pharmaceutical
The major cancers such as breast, colon and non-small-cell lung carcinoma (NSCLC) are being examined for efficacy with c-MET / HGF inhibitors. Several small molecule c-Met kinase inhibitors have demonstrated clinical efficacy in cancer treatment and many clinical trials are underway. However, as the small molecule inhibitors lack specificity or selectivity they can cause toxicity. Therefore, researchers are increasing focus to develop antibody therapeutics against c-Met or HGF.
Market Analysis and Insights: Global C-MET / HGF Inhibitors Market
The global C-MET / HGF Inhibitors market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
Global C-MET / HGF Inhibitors Scope and Segment
The global C-MET / HGF Inhibitors market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global C-MET / HGF Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
The major regions covered in the report are North America, Europe, Asia-Pacific, South America, Middle East & Africa, etc. The report has specifically covered major countries including U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc. It includes revenue and volume analysis of each region and their respective countries for the forecast years. It also contains country-wise volume and revenue from the year 2016 to 2021. Additionally, it provides the reader with accurate data on volume sales according to the consumption for the same years.
By the product type, the market is primarily split into
C-Met Biologic Inhibitors
Small Molecule C-Met Inhibitors
HGF Antagonist Antibodies
C-Met Antagonist Antibodies(MetMAb)
HGF Kringle Variant Antagonists
By the end users/application, this report covers the following segments
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Sales
Competitive Landscape:
The report provides a list of all the key players in the C-MET / HGF Inhibitors market along with a detailed analysis of the strategies, which the companies are adopting. The strategies mainly include new product Developments, research, and Developments, and also provides revenue shares, company overview, and recent company Developments to remain competitive in the market.
The C-MET / HGF Inhibitors key manufacturers in this market include:
Abxign
Abbott Laboratories
Amgen
ArQule
Astex Therapeutics
AVEO Pharmaceuticals
Bristol-Myers Squibb(BMS)
Chroma Therapeutics
Daiichi Sankyo
Deciphera Pharmaceuticals
Eisai
Eli Lilly
Exelixis
Genmab
Galaxy Biotech
GlaxoSmithKline(GSK)
Hutchison MediPharma
Johnson & Johnson
Kringle Pharmaceuticals
Merck
Methylgene
Novartis
Pfizer
ProMetic BioTherapeutics
Takeda Pharmaceutical
1 C-MET / HGF Inhibitors Market Overview
1.1 C-MET / HGF Inhibitors Product Overview
1.2 C-MET / HGF Inhibitors Market Segment by Type
1.2.1 C-Met Biologic Inhibitors
1.2.2 Small Molecule C-Met Inhibitors
1.2.3 HGF Antagonist Antibodies
1.2.4 C-Met Antagonist Antibodies(MetMAb)
1.2.5 HGF Kringle Variant Antagonists
1.3 Global C-MET / HGF Inhibitors Market Size by Type
1.3.1 Global C-MET / HGF Inhibitors Market Size Overview by Type (2016-2027)
1.3.2 Global C-MET / HGF Inhibitors Historic Market Size Review by Type (2016-2021)
1.3.2.1 Global C-MET / HGF Inhibitors Sales Breakdown in Volume by Type (2016-2021)
1.3.2.2 Global C-MET / HGF Inhibitors Sales Breakdown in Value by Type (2016-2021)
1.3.2.3 Global C-MET / HGF Inhibitors Average Selling Price (ASP) by Type (2016-2021)
1.3.3 Global C-MET / HGF Inhibitors Forecasted Market Size by Type (2022-2027)
1.3.3.1 Global C-MET / HGF Inhibitors Sales Breakdown in Volume by Type (2022-2027)
1.3.3.2 Global C-MET / HGF Inhibitors Sales Breakdown in Value by Type (2022-2027)
1.3.3.3 Global C-MET / HGF Inhibitors Average Selling Price (ASP) by Type (2022-2027)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America C-MET / HGF Inhibitors Sales Breakdown by Type (2016-2021)
1.4.2 Europe C-MET / HGF Inhibitors Sales Breakdown by Type (2016-2021)
1.4.3 Asia-Pacific C-MET / HGF Inhibitors Sales Breakdown by Type (2016-2021)
1.4.4 Latin America C-MET / HGF Inhibitors Sales Breakdown by Type (2016-2021)
1.4.5 Middle East and Africa C-MET / HGF Inhibitors Sales Breakdown by Type (2016-2021)
2 Global C-MET / HGF Inhibitors Market Competition by Company
2.1 Global Top Players by C-MET / HGF Inhibitors Sales (2016-2021)
2.2 Global Top Players by C-MET / HGF Inhibitors Revenue (2016-2021)
2.3 Global Top Players C-MET / HGF Inhibitors Price (2016-2021)
2.4 Global Top Manufacturers C-MET / HGF Inhibitors Manufacturing Base Distribution, Sales Area, Product Type
2.5 C-MET / HGF Inhibitors Market Competitive Situation and Trends
2.5.1 C-MET / HGF Inhibitors Market Concentration Rate (2016-2021)
2.5.2 Global 5 and 10 Largest Manufacturers by C-MET / HGF Inhibitors Sales and Revenue in 2020
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in C-MET / HGF Inhibitors as of 2020)
2.7 Date of Key Manufacturers Enter into C-MET / HGF Inhibitors Market
2.8 Key Manufacturers C-MET / HGF Inhibitors Product Offered
2.9 Mergers & Acquisitions, Expansion
3 C-MET / HGF Inhibitors Status and Outlook by Region
3.1 Global C-MET / HGF Inhibitors Market Size and CAGR by Region: 2016 VS 2021 VS 2026
3.2 Global C-MET / HGF Inhibitors Historic Market Size by Region
3.2.1 Global C-MET / HGF Inhibitors Sales in Volume by Region (2016-2021)
3.2.2 Global C-MET / HGF Inhibitors Sales in Value by Region (2016-2021)
3.2.3 Global C-MET / HGF Inhibitors Sales (Volume & Value) Price and Gross Margin (2016-2021)
3.3 Global C-MET / HGF Inhibitors Forecasted Market Size by Region
3.3.1 Global C-MET / HGF Inhibitors Sales in Volume by Region (2022-2027)
3.3.2 Global C-MET / HGF Inhibitors Sales in Value by Region (2022-2027)
3.3.3 Global C-MET / HGF Inhibitors Sales (Volume & Value), Price and Gross Margin (2022-2027)
4 Global C-MET / HGF Inhibitors by Application
4.1 C-MET / HGF Inhibitors Market Segment by Application
4.1.1 Hospital Pharmacies
4.1.2 Retail Pharmacies
4.1.3 Drug Stores
4.1.4 Online Sales
4.2 Global C-MET / HGF Inhibitors Market Size by Application
4.2.1 Global C-MET / HGF Inhibitors Market Size Overview by Application (2016-2027)
4.2.2 Global C-MET / HGF Inhibitors Historic Market Size Review by Application (2016-2021)
4.2.2.1 Global C-MET / HGF Inhibitors Sales Breakdown in Volume, by Application (2016-2021)
4.2.2.2 Global C-MET / HGF Inhibitors Sales Breakdown in Value, by Application (2016-2021)
4.2.2.3 Global C-MET / HGF Inhibitors Average Selling Price (ASP) by Application (2016-2021)
4.2.3 Global C-MET / HGF Inhibitors Forecasted Market Size by Application (2022-2027)
4.2.3.1 Global C-MET / HGF Inhibitors Sales Breakdown in Volume, by Application (2022-2027)
4.2.3.2 Global C-MET / HGF Inhibitors Sales Breakdown in Value, by Application (2022-2027)
4.2.3.3 Global C-MET / HGF Inhibitors Average Selling Price (ASP) by Application (2022-2027)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America C-MET / HGF Inhibitors Sales Breakdown by Application (2016-2021)
4.3.2 Europe C-MET / HGF Inhibitors Sales Breakdown by Application (2016-2021)
4.3.3 Asia-Pacific C-MET / HGF Inhibitors Sales Breakdown by Application (2016-2021)
4.3.4 Latin America C-MET / HGF Inhibitors Sales Breakdown by Application (2016-2021)
4.3.5 Middle East and Africa C-MET / HGF Inhibitors Sales Breakdown by Application (2016-2021)
5 North America C-MET / HGF Inhibitors by Country
5.1 North America C-MET / HGF Inhibitors Historic Market Size by Country
5.1.1 North America C-MET / HGF Inhibitors Sales in Volume by Country (2016-2021)
5.1.2 North America C-MET / HGF Inhibitors Sales in Value by Country (2016-2021)
5.2 North America C-MET / HGF Inhibitors Forecasted Market Size by Country
5.2.1 North America C-MET / HGF Inhibitors Sales in Volume by Country (2022-2027)
5.2.2 North America C-MET / HGF Inhibitors Sales in Value by Country (2022-2027)
6 Europe C-MET / HGF Inhibitors by Country
6.1 Europe C-MET / HGF Inhibitors Historic Market Size by Country
6.1.1 Europe C-MET / HGF Inhibitors Sales in Volume by Country (2016-2021)
6.1.2 Europe C-MET / HGF Inhibitors Sales in Value by Country (2016-2021)
6.2 Europe C-MET / HGF Inhibitors Forecasted Market Size by Country
6.2.1 Europe C-MET / HGF Inhibitors Sales in Volume by Country (2022-2027)
6.2.2 Europe C-MET / HGF Inhibitors Sales in Value by Country (2022-2027)
7 Asia-Pacific C-MET / HGF Inhibitors by Region
7.1 Asia-Pacific C-MET / HGF Inhibitors Historic Market Size by Region
7.1.1 Asia-Pacific C-MET / HGF Inhibitors Sales in Volume by Region (2016-2021)
7.1.2 Asia-Pacific C-MET / HGF Inhibitors Sales in Value by Region (2016-2021)
7.2 Asia-Pacific C-MET / HGF Inhibitors Forecasted Market Size by Region
7.2.1 Asia-Pacific C-MET / HGF Inhibitors Sales in Volume by Region (2022-2027)
7.2.2 Asia-Pacific C-MET / HGF Inhibitors Sales in Value by Region (2022-2027)
8 Latin America C-MET / HGF Inhibitors by Country
8.1 Latin America C-MET / HGF Inhibitors Historic Market Size by Country
8.1.1 Latin America C-MET / HGF Inhibitors Sales in Volume by Country (2016-2021)
8.1.2 Latin America C-MET / HGF Inhibitors Sales in Value by Country (2016-2021)
8.2 Latin America C-MET / HGF Inhibitors Forecasted Market Size by Country
8.2.1 Latin America C-MET / HGF Inhibitors Sales in Volume by Country (2022-2027)
8.2.2 Latin America C-MET / HGF Inhibitors Sales in Value by Country (2022-2027)
9 Middle East and Africa C-MET / HGF Inhibitors by Country
9.1 Middle East and Africa C-MET / HGF Inhibitors Historic Market Size by Country
9.1.1 Middle East and Africa C-MET / HGF Inhibitors Sales in Volume by Country (2016-2021)
9.1.2 Middle East and Africa C-MET / HGF Inhibitors Sales in Value by Country (2016-2021)
9.2 Middle East and Africa C-MET / HGF Inhibitors Forecasted Market Size by Country
9.2.1 Middle East and Africa C-MET / HGF Inhibitors Sales in Volume by Country (2022-2027)
9.2.2 Middle East and Africa C-MET / HGF Inhibitors Sales in Value by Country (2022-2027)
10 Company Profiles and Key Figures in C-MET / HGF Inhibitors Business
10.1 Abxign
10.1.1 Abxign Corporation Information
10.1.2 Abxign Introduction and Business Overview
10.1.3 Abxign C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.1.4 Abxign C-MET / HGF Inhibitors Products Offered
10.1.5 Abxign Recent Development
10.2 Abbott Laboratories
10.2.1 Abbott Laboratories Corporation Information
10.2.2 Abbott Laboratories Introduction and Business Overview
10.2.3 Abbott Laboratories C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.2.4 Abxign C-MET / HGF Inhibitors Products Offered
10.2.5 Abbott Laboratories Recent Development
10.3 Amgen
10.3.1 Amgen Corporation Information
10.3.2 Amgen Introduction and Business Overview
10.3.3 Amgen C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.3.4 Amgen C-MET / HGF Inhibitors Products Offered
10.3.5 Amgen Recent Development
10.4 ArQule
10.4.1 ArQule Corporation Information
10.4.2 ArQule Introduction and Business Overview
10.4.3 ArQule C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.4.4 ArQule C-MET / HGF Inhibitors Products Offered
10.4.5 ArQule Recent Development
10.5 Astex Therapeutics
10.5.1 Astex Therapeutics Corporation Information
10.5.2 Astex Therapeutics Introduction and Business Overview
10.5.3 Astex Therapeutics C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.5.4 Astex Therapeutics C-MET / HGF Inhibitors Products Offered
10.5.5 Astex Therapeutics Recent Development
10.6 AVEO Pharmaceuticals
10.6.1 AVEO Pharmaceuticals Corporation Information
10.6.2 AVEO Pharmaceuticals Introduction and Business Overview
10.6.3 AVEO Pharmaceuticals C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.6.4 AVEO Pharmaceuticals C-MET / HGF Inhibitors Products Offered
10.6.5 AVEO Pharmaceuticals Recent Development
10.7 Bristol-Myers Squibb(BMS)
10.7.1 Bristol-Myers Squibb(BMS) Corporation Information
10.7.2 Bristol-Myers Squibb(BMS) Introduction and Business Overview
10.7.3 Bristol-Myers Squibb(BMS) C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.7.4 Bristol-Myers Squibb(BMS) C-MET / HGF Inhibitors Products Offered
10.7.5 Bristol-Myers Squibb(BMS) Recent Development
10.8 Chroma Therapeutics
10.8.1 Chroma Therapeutics Corporation Information
10.8.2 Chroma Therapeutics Introduction and Business Overview
10.8.3 Chroma Therapeutics C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.8.4 Chroma Therapeutics C-MET / HGF Inhibitors Products Offered
10.8.5 Chroma Therapeutics Recent Development
10.9 Daiichi Sankyo
10.9.1 Daiichi Sankyo Corporation Information
10.9.2 Daiichi Sankyo Introduction and Business Overview
10.9.3 Daiichi Sankyo C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.9.4 Daiichi Sankyo C-MET / HGF Inhibitors Products Offered
10.9.5 Daiichi Sankyo Recent Development
10.10 Deciphera Pharmaceuticals
10.10.1 Company Basic Information, Manufacturing Base and Competitors
10.10.2 C-MET / HGF Inhibitors Product Category, Application and Specification
10.10.3 Deciphera Pharmaceuticals C-MET / HGF Inhibitors Sales, Revenue, Price and Gross Margin (2016-2021)
10.10.4 Main Business Overview
10.10.5 Deciphera Pharmaceuticals Recent Development
10.11 Eisai
10.11.1 Eisai Corporation Information
10.11.2 Eisai Introduction and Business Overview
10.11.3 Eisai C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.11.4 Eisai C-MET / HGF Inhibitors Products Offered
10.11.5 Eisai Recent Development
10.12 Eli Lilly
10.12.1 Eli Lilly Corporation Information
10.12.2 Eli Lilly Introduction and Business Overview
10.12.3 Eli Lilly C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.12.4 Eli Lilly C-MET / HGF Inhibitors Products Offered
10.12.5 Eli Lilly Recent Development
10.13 Exelixis
10.13.1 Exelixis Corporation Information
10.13.2 Exelixis Introduction and Business Overview
10.13.3 Exelixis C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.13.4 Exelixis C-MET / HGF Inhibitors Products Offered
10.13.5 Exelixis Recent Development
10.14 Genmab
10.14.1 Genmab Corporation Information
10.14.2 Genmab Introduction and Business Overview
10.14.3 Genmab C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.14.4 Genmab C-MET / HGF Inhibitors Products Offered
10.14.5 Genmab Recent Development
10.15 Galaxy Biotech
10.15.1 Galaxy Biotech Corporation Information
10.15.2 Galaxy Biotech Introduction and Business Overview
10.15.3 Galaxy Biotech C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.15.4 Galaxy Biotech C-MET / HGF Inhibitors Products Offered
10.15.5 Galaxy Biotech Recent Development
10.16 GlaxoSmithKline(GSK)
10.16.1 GlaxoSmithKline(GSK) Corporation Information
10.16.2 GlaxoSmithKline(GSK) Introduction and Business Overview
10.16.3 GlaxoSmithKline(GSK) C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.16.4 GlaxoSmithKline(GSK) C-MET / HGF Inhibitors Products Offered
10.16.5 GlaxoSmithKline(GSK) Recent Development
10.17 Hutchison MediPharma
10.17.1 Hutchison MediPharma Corporation Information
10.17.2 Hutchison MediPharma Introduction and Business Overview
10.17.3 Hutchison MediPharma C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.17.4 Hutchison MediPharma C-MET / HGF Inhibitors Products Offered
10.17.5 Hutchison MediPharma Recent Development
10.18 Johnson & Johnson
10.18.1 Johnson & Johnson Corporation Information
10.18.2 Johnson & Johnson Introduction and Business Overview
10.18.3 Johnson & Johnson C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.18.4 Johnson & Johnson C-MET / HGF Inhibitors Products Offered
10.18.5 Johnson & Johnson Recent Development
10.19 Kringle Pharmaceuticals
10.19.1 Kringle Pharmaceuticals Corporation Information
10.19.2 Kringle Pharmaceuticals Introduction and Business Overview
10.19.3 Kringle Pharmaceuticals C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.19.4 Kringle Pharmaceuticals C-MET / HGF Inhibitors Products Offered
10.19.5 Kringle Pharmaceuticals Recent Development
10.20 Merck
10.20.1 Merck Corporation Information
10.20.2 Merck Introduction and Business Overview
10.20.3 Merck C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.20.4 Merck C-MET / HGF Inhibitors Products Offered
10.20.5 Merck Recent Development
10.21 Methylgene
10.21.1 Methylgene Corporation Information
10.21.2 Methylgene Introduction and Business Overview
10.21.3 Methylgene C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.21.4 Methylgene C-MET / HGF Inhibitors Products Offered
10.21.5 Methylgene Recent Development
10.22 Novartis
10.22.1 Novartis Corporation Information
10.22.2 Novartis Introduction and Business Overview
10.22.3 Novartis C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.22.4 Novartis C-MET / HGF Inhibitors Products Offered
10.22.5 Novartis Recent Development
10.23 Pfizer
10.23.1 Pfizer Corporation Information
10.23.2 Pfizer Introduction and Business Overview
10.23.3 Pfizer C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.23.4 Pfizer C-MET / HGF Inhibitors Products Offered
10.23.5 Pfizer Recent Development
10.24 ProMetic BioTherapeutics
10.24.1 ProMetic BioTherapeutics Corporation Information
10.24.2 ProMetic BioTherapeutics Introduction and Business Overview
10.24.3 ProMetic BioTherapeutics C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.24.4 ProMetic BioTherapeutics C-MET / HGF Inhibitors Products Offered
10.24.5 ProMetic BioTherapeutics Recent Development
10.25 Takeda Pharmaceutical
10.25.1 Takeda Pharmaceutical Corporation Information
10.25.2 Takeda Pharmaceutical Introduction and Business Overview
10.25.3 Takeda Pharmaceutical C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.25.4 Takeda Pharmaceutical C-MET / HGF Inhibitors Products Offered
10.25.5 Takeda Pharmaceutical Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 C-MET / HGF Inhibitors Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 C-MET / HGF Inhibitors Industrial Chain Analysis
11.4 C-MET / HGF Inhibitors Market Dynamics
11.4.1 Industry Trends
11.4.2 Market Drivers
11.4.3 Market Challenges
11.4.4 Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 C-MET / HGF Inhibitors Distributors
12.3 C-MET / HGF Inhibitors Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
1.1 C-MET / HGF Inhibitors Product Overview
1.2 C-MET / HGF Inhibitors Market Segment by Type
1.2.1 C-Met Biologic Inhibitors
1.2.2 Small Molecule C-Met Inhibitors
1.2.3 HGF Antagonist Antibodies
1.2.4 C-Met Antagonist Antibodies(MetMAb)
1.2.5 HGF Kringle Variant Antagonists
1.3 Global C-MET / HGF Inhibitors Market Size by Type
1.3.1 Global C-MET / HGF Inhibitors Market Size Overview by Type (2016-2027)
1.3.2 Global C-MET / HGF Inhibitors Historic Market Size Review by Type (2016-2021)
1.3.2.1 Global C-MET / HGF Inhibitors Sales Breakdown in Volume by Type (2016-2021)
1.3.2.2 Global C-MET / HGF Inhibitors Sales Breakdown in Value by Type (2016-2021)
1.3.2.3 Global C-MET / HGF Inhibitors Average Selling Price (ASP) by Type (2016-2021)
1.3.3 Global C-MET / HGF Inhibitors Forecasted Market Size by Type (2022-2027)
1.3.3.1 Global C-MET / HGF Inhibitors Sales Breakdown in Volume by Type (2022-2027)
1.3.3.2 Global C-MET / HGF Inhibitors Sales Breakdown in Value by Type (2022-2027)
1.3.3.3 Global C-MET / HGF Inhibitors Average Selling Price (ASP) by Type (2022-2027)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America C-MET / HGF Inhibitors Sales Breakdown by Type (2016-2021)
1.4.2 Europe C-MET / HGF Inhibitors Sales Breakdown by Type (2016-2021)
1.4.3 Asia-Pacific C-MET / HGF Inhibitors Sales Breakdown by Type (2016-2021)
1.4.4 Latin America C-MET / HGF Inhibitors Sales Breakdown by Type (2016-2021)
1.4.5 Middle East and Africa C-MET / HGF Inhibitors Sales Breakdown by Type (2016-2021)
2 Global C-MET / HGF Inhibitors Market Competition by Company
2.1 Global Top Players by C-MET / HGF Inhibitors Sales (2016-2021)
2.2 Global Top Players by C-MET / HGF Inhibitors Revenue (2016-2021)
2.3 Global Top Players C-MET / HGF Inhibitors Price (2016-2021)
2.4 Global Top Manufacturers C-MET / HGF Inhibitors Manufacturing Base Distribution, Sales Area, Product Type
2.5 C-MET / HGF Inhibitors Market Competitive Situation and Trends
2.5.1 C-MET / HGF Inhibitors Market Concentration Rate (2016-2021)
2.5.2 Global 5 and 10 Largest Manufacturers by C-MET / HGF Inhibitors Sales and Revenue in 2020
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in C-MET / HGF Inhibitors as of 2020)
2.7 Date of Key Manufacturers Enter into C-MET / HGF Inhibitors Market
2.8 Key Manufacturers C-MET / HGF Inhibitors Product Offered
2.9 Mergers & Acquisitions, Expansion
3 C-MET / HGF Inhibitors Status and Outlook by Region
3.1 Global C-MET / HGF Inhibitors Market Size and CAGR by Region: 2016 VS 2021 VS 2026
3.2 Global C-MET / HGF Inhibitors Historic Market Size by Region
3.2.1 Global C-MET / HGF Inhibitors Sales in Volume by Region (2016-2021)
3.2.2 Global C-MET / HGF Inhibitors Sales in Value by Region (2016-2021)
3.2.3 Global C-MET / HGF Inhibitors Sales (Volume & Value) Price and Gross Margin (2016-2021)
3.3 Global C-MET / HGF Inhibitors Forecasted Market Size by Region
3.3.1 Global C-MET / HGF Inhibitors Sales in Volume by Region (2022-2027)
3.3.2 Global C-MET / HGF Inhibitors Sales in Value by Region (2022-2027)
3.3.3 Global C-MET / HGF Inhibitors Sales (Volume & Value), Price and Gross Margin (2022-2027)
4 Global C-MET / HGF Inhibitors by Application
4.1 C-MET / HGF Inhibitors Market Segment by Application
4.1.1 Hospital Pharmacies
4.1.2 Retail Pharmacies
4.1.3 Drug Stores
4.1.4 Online Sales
4.2 Global C-MET / HGF Inhibitors Market Size by Application
4.2.1 Global C-MET / HGF Inhibitors Market Size Overview by Application (2016-2027)
4.2.2 Global C-MET / HGF Inhibitors Historic Market Size Review by Application (2016-2021)
4.2.2.1 Global C-MET / HGF Inhibitors Sales Breakdown in Volume, by Application (2016-2021)
4.2.2.2 Global C-MET / HGF Inhibitors Sales Breakdown in Value, by Application (2016-2021)
4.2.2.3 Global C-MET / HGF Inhibitors Average Selling Price (ASP) by Application (2016-2021)
4.2.3 Global C-MET / HGF Inhibitors Forecasted Market Size by Application (2022-2027)
4.2.3.1 Global C-MET / HGF Inhibitors Sales Breakdown in Volume, by Application (2022-2027)
4.2.3.2 Global C-MET / HGF Inhibitors Sales Breakdown in Value, by Application (2022-2027)
4.2.3.3 Global C-MET / HGF Inhibitors Average Selling Price (ASP) by Application (2022-2027)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America C-MET / HGF Inhibitors Sales Breakdown by Application (2016-2021)
4.3.2 Europe C-MET / HGF Inhibitors Sales Breakdown by Application (2016-2021)
4.3.3 Asia-Pacific C-MET / HGF Inhibitors Sales Breakdown by Application (2016-2021)
4.3.4 Latin America C-MET / HGF Inhibitors Sales Breakdown by Application (2016-2021)
4.3.5 Middle East and Africa C-MET / HGF Inhibitors Sales Breakdown by Application (2016-2021)
5 North America C-MET / HGF Inhibitors by Country
5.1 North America C-MET / HGF Inhibitors Historic Market Size by Country
5.1.1 North America C-MET / HGF Inhibitors Sales in Volume by Country (2016-2021)
5.1.2 North America C-MET / HGF Inhibitors Sales in Value by Country (2016-2021)
5.2 North America C-MET / HGF Inhibitors Forecasted Market Size by Country
5.2.1 North America C-MET / HGF Inhibitors Sales in Volume by Country (2022-2027)
5.2.2 North America C-MET / HGF Inhibitors Sales in Value by Country (2022-2027)
6 Europe C-MET / HGF Inhibitors by Country
6.1 Europe C-MET / HGF Inhibitors Historic Market Size by Country
6.1.1 Europe C-MET / HGF Inhibitors Sales in Volume by Country (2016-2021)
6.1.2 Europe C-MET / HGF Inhibitors Sales in Value by Country (2016-2021)
6.2 Europe C-MET / HGF Inhibitors Forecasted Market Size by Country
6.2.1 Europe C-MET / HGF Inhibitors Sales in Volume by Country (2022-2027)
6.2.2 Europe C-MET / HGF Inhibitors Sales in Value by Country (2022-2027)
7 Asia-Pacific C-MET / HGF Inhibitors by Region
7.1 Asia-Pacific C-MET / HGF Inhibitors Historic Market Size by Region
7.1.1 Asia-Pacific C-MET / HGF Inhibitors Sales in Volume by Region (2016-2021)
7.1.2 Asia-Pacific C-MET / HGF Inhibitors Sales in Value by Region (2016-2021)
7.2 Asia-Pacific C-MET / HGF Inhibitors Forecasted Market Size by Region
7.2.1 Asia-Pacific C-MET / HGF Inhibitors Sales in Volume by Region (2022-2027)
7.2.2 Asia-Pacific C-MET / HGF Inhibitors Sales in Value by Region (2022-2027)
8 Latin America C-MET / HGF Inhibitors by Country
8.1 Latin America C-MET / HGF Inhibitors Historic Market Size by Country
8.1.1 Latin America C-MET / HGF Inhibitors Sales in Volume by Country (2016-2021)
8.1.2 Latin America C-MET / HGF Inhibitors Sales in Value by Country (2016-2021)
8.2 Latin America C-MET / HGF Inhibitors Forecasted Market Size by Country
8.2.1 Latin America C-MET / HGF Inhibitors Sales in Volume by Country (2022-2027)
8.2.2 Latin America C-MET / HGF Inhibitors Sales in Value by Country (2022-2027)
9 Middle East and Africa C-MET / HGF Inhibitors by Country
9.1 Middle East and Africa C-MET / HGF Inhibitors Historic Market Size by Country
9.1.1 Middle East and Africa C-MET / HGF Inhibitors Sales in Volume by Country (2016-2021)
9.1.2 Middle East and Africa C-MET / HGF Inhibitors Sales in Value by Country (2016-2021)
9.2 Middle East and Africa C-MET / HGF Inhibitors Forecasted Market Size by Country
9.2.1 Middle East and Africa C-MET / HGF Inhibitors Sales in Volume by Country (2022-2027)
9.2.2 Middle East and Africa C-MET / HGF Inhibitors Sales in Value by Country (2022-2027)
10 Company Profiles and Key Figures in C-MET / HGF Inhibitors Business
10.1 Abxign
10.1.1 Abxign Corporation Information
10.1.2 Abxign Introduction and Business Overview
10.1.3 Abxign C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.1.4 Abxign C-MET / HGF Inhibitors Products Offered
10.1.5 Abxign Recent Development
10.2 Abbott Laboratories
10.2.1 Abbott Laboratories Corporation Information
10.2.2 Abbott Laboratories Introduction and Business Overview
10.2.3 Abbott Laboratories C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.2.4 Abxign C-MET / HGF Inhibitors Products Offered
10.2.5 Abbott Laboratories Recent Development
10.3 Amgen
10.3.1 Amgen Corporation Information
10.3.2 Amgen Introduction and Business Overview
10.3.3 Amgen C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.3.4 Amgen C-MET / HGF Inhibitors Products Offered
10.3.5 Amgen Recent Development
10.4 ArQule
10.4.1 ArQule Corporation Information
10.4.2 ArQule Introduction and Business Overview
10.4.3 ArQule C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.4.4 ArQule C-MET / HGF Inhibitors Products Offered
10.4.5 ArQule Recent Development
10.5 Astex Therapeutics
10.5.1 Astex Therapeutics Corporation Information
10.5.2 Astex Therapeutics Introduction and Business Overview
10.5.3 Astex Therapeutics C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.5.4 Astex Therapeutics C-MET / HGF Inhibitors Products Offered
10.5.5 Astex Therapeutics Recent Development
10.6 AVEO Pharmaceuticals
10.6.1 AVEO Pharmaceuticals Corporation Information
10.6.2 AVEO Pharmaceuticals Introduction and Business Overview
10.6.3 AVEO Pharmaceuticals C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.6.4 AVEO Pharmaceuticals C-MET / HGF Inhibitors Products Offered
10.6.5 AVEO Pharmaceuticals Recent Development
10.7 Bristol-Myers Squibb(BMS)
10.7.1 Bristol-Myers Squibb(BMS) Corporation Information
10.7.2 Bristol-Myers Squibb(BMS) Introduction and Business Overview
10.7.3 Bristol-Myers Squibb(BMS) C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.7.4 Bristol-Myers Squibb(BMS) C-MET / HGF Inhibitors Products Offered
10.7.5 Bristol-Myers Squibb(BMS) Recent Development
10.8 Chroma Therapeutics
10.8.1 Chroma Therapeutics Corporation Information
10.8.2 Chroma Therapeutics Introduction and Business Overview
10.8.3 Chroma Therapeutics C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.8.4 Chroma Therapeutics C-MET / HGF Inhibitors Products Offered
10.8.5 Chroma Therapeutics Recent Development
10.9 Daiichi Sankyo
10.9.1 Daiichi Sankyo Corporation Information
10.9.2 Daiichi Sankyo Introduction and Business Overview
10.9.3 Daiichi Sankyo C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.9.4 Daiichi Sankyo C-MET / HGF Inhibitors Products Offered
10.9.5 Daiichi Sankyo Recent Development
10.10 Deciphera Pharmaceuticals
10.10.1 Company Basic Information, Manufacturing Base and Competitors
10.10.2 C-MET / HGF Inhibitors Product Category, Application and Specification
10.10.3 Deciphera Pharmaceuticals C-MET / HGF Inhibitors Sales, Revenue, Price and Gross Margin (2016-2021)
10.10.4 Main Business Overview
10.10.5 Deciphera Pharmaceuticals Recent Development
10.11 Eisai
10.11.1 Eisai Corporation Information
10.11.2 Eisai Introduction and Business Overview
10.11.3 Eisai C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.11.4 Eisai C-MET / HGF Inhibitors Products Offered
10.11.5 Eisai Recent Development
10.12 Eli Lilly
10.12.1 Eli Lilly Corporation Information
10.12.2 Eli Lilly Introduction and Business Overview
10.12.3 Eli Lilly C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.12.4 Eli Lilly C-MET / HGF Inhibitors Products Offered
10.12.5 Eli Lilly Recent Development
10.13 Exelixis
10.13.1 Exelixis Corporation Information
10.13.2 Exelixis Introduction and Business Overview
10.13.3 Exelixis C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.13.4 Exelixis C-MET / HGF Inhibitors Products Offered
10.13.5 Exelixis Recent Development
10.14 Genmab
10.14.1 Genmab Corporation Information
10.14.2 Genmab Introduction and Business Overview
10.14.3 Genmab C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.14.4 Genmab C-MET / HGF Inhibitors Products Offered
10.14.5 Genmab Recent Development
10.15 Galaxy Biotech
10.15.1 Galaxy Biotech Corporation Information
10.15.2 Galaxy Biotech Introduction and Business Overview
10.15.3 Galaxy Biotech C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.15.4 Galaxy Biotech C-MET / HGF Inhibitors Products Offered
10.15.5 Galaxy Biotech Recent Development
10.16 GlaxoSmithKline(GSK)
10.16.1 GlaxoSmithKline(GSK) Corporation Information
10.16.2 GlaxoSmithKline(GSK) Introduction and Business Overview
10.16.3 GlaxoSmithKline(GSK) C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.16.4 GlaxoSmithKline(GSK) C-MET / HGF Inhibitors Products Offered
10.16.5 GlaxoSmithKline(GSK) Recent Development
10.17 Hutchison MediPharma
10.17.1 Hutchison MediPharma Corporation Information
10.17.2 Hutchison MediPharma Introduction and Business Overview
10.17.3 Hutchison MediPharma C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.17.4 Hutchison MediPharma C-MET / HGF Inhibitors Products Offered
10.17.5 Hutchison MediPharma Recent Development
10.18 Johnson & Johnson
10.18.1 Johnson & Johnson Corporation Information
10.18.2 Johnson & Johnson Introduction and Business Overview
10.18.3 Johnson & Johnson C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.18.4 Johnson & Johnson C-MET / HGF Inhibitors Products Offered
10.18.5 Johnson & Johnson Recent Development
10.19 Kringle Pharmaceuticals
10.19.1 Kringle Pharmaceuticals Corporation Information
10.19.2 Kringle Pharmaceuticals Introduction and Business Overview
10.19.3 Kringle Pharmaceuticals C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.19.4 Kringle Pharmaceuticals C-MET / HGF Inhibitors Products Offered
10.19.5 Kringle Pharmaceuticals Recent Development
10.20 Merck
10.20.1 Merck Corporation Information
10.20.2 Merck Introduction and Business Overview
10.20.3 Merck C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.20.4 Merck C-MET / HGF Inhibitors Products Offered
10.20.5 Merck Recent Development
10.21 Methylgene
10.21.1 Methylgene Corporation Information
10.21.2 Methylgene Introduction and Business Overview
10.21.3 Methylgene C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.21.4 Methylgene C-MET / HGF Inhibitors Products Offered
10.21.5 Methylgene Recent Development
10.22 Novartis
10.22.1 Novartis Corporation Information
10.22.2 Novartis Introduction and Business Overview
10.22.3 Novartis C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.22.4 Novartis C-MET / HGF Inhibitors Products Offered
10.22.5 Novartis Recent Development
10.23 Pfizer
10.23.1 Pfizer Corporation Information
10.23.2 Pfizer Introduction and Business Overview
10.23.3 Pfizer C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.23.4 Pfizer C-MET / HGF Inhibitors Products Offered
10.23.5 Pfizer Recent Development
10.24 ProMetic BioTherapeutics
10.24.1 ProMetic BioTherapeutics Corporation Information
10.24.2 ProMetic BioTherapeutics Introduction and Business Overview
10.24.3 ProMetic BioTherapeutics C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.24.4 ProMetic BioTherapeutics C-MET / HGF Inhibitors Products Offered
10.24.5 ProMetic BioTherapeutics Recent Development
10.25 Takeda Pharmaceutical
10.25.1 Takeda Pharmaceutical Corporation Information
10.25.2 Takeda Pharmaceutical Introduction and Business Overview
10.25.3 Takeda Pharmaceutical C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021)
10.25.4 Takeda Pharmaceutical C-MET / HGF Inhibitors Products Offered
10.25.5 Takeda Pharmaceutical Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 C-MET / HGF Inhibitors Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 C-MET / HGF Inhibitors Industrial Chain Analysis
11.4 C-MET / HGF Inhibitors Market Dynamics
11.4.1 Industry Trends
11.4.2 Market Drivers
11.4.3 Market Challenges
11.4.4 Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 C-MET / HGF Inhibitors Distributors
12.3 C-MET / HGF Inhibitors Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
